Ovarian cancer in elderly women

International Journal of Gynecological Cancer

Volumn 7, Issue SUPPL. 1, 1997, Pages 23-26

  Conte, P F ^a   Romanini, A ^a   Brunetti, I ^a   Giannessi, P ^a   Fanucchi, A ^a   Gadducci, A ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Carboplatin; Elderly patients; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; PLATINUM DERIVATIVE; VINBLASTINE;

AGED; AGING; CANCER INCIDENCE; CONFERENCE PAPER; DRUG METABOLISM; FEMALE; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0030810784     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.7.s1.2.x     Document Type: Conference Paper

References (37)

1. Ovarian cancer incidence: distribution by age. J Natl Cancer Inst 1995; 87: 280.
2. Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma. Cancer 1993; 71 (Suppl.): 606-14.
3. Alberts DS, Dahlberg S, Green SJ, et al. Analysis of patients' age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stage III (suboptimal) and IV ovarian cancer. Cancer 1993; 71 (Suppl.): 618-27.
4. Riess LAG, Hankey BF, Miller BA, et al. Cancer Statistics Review 1973-1988. Bethesda, Maryland: National Institutes of Health, National Cancer Institute, NIH 91-2789, 1991.
5. Timer N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Ann Rev Pharmacol Toxicol 1992; 32: 271-302.
6. Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism 1978; 19: 653-63.
7. Sotariano WA, Ragland DA. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120: 104-10.
8. Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol 1993; 20: 43-9.
9. Balducci L, Mowry K. Pharmacology and organ toxicity of chemotherapy in older patients. Oncology 1992; 6 (Suppl. 1): 62-8.
10. Barkowski JM, Duan M, Dantower RC, et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 1994; 33: 493-6.
11. Lipschitz DA. Age-related declines in hematopoietic reserve capacity. Semin Oncol 1995; 22 (Suppl. 1): 3-5.
12. Hartock RJ, Smith EB, Petty C. Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest. Am J Clin Pathol 1965; 43: 3626-31.
13. Begg CB, Elson PJ, Carbone PP. A study of excess hematologic toxicity in elderly patients treated on cancer chemotherapy protocols. In: Yancik K, Yates JW, eds. Cancer in the Elderly. An Approach to Early Detection and Treatment. New York: Springer Verlag, 1989: 149-63.
14. Giovanazzi-Borman S, Rademaker A, Loi G, et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center Study. J Clin Oncol 1994; 12: 2447-52.
15. Folkow B, Svanborg A. Physiology of cardiovascular aging. Physiol Rev 1993; 73: 725-64.
16. von Hoff DD, Lavard MW, Bosa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-17.
17. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745-52.
18. Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. Monogr Natl Cancer Inst 1993; 15: 117-30.
19. Balducci L, Parker M, Sexton W, et al. Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 1989; 16: 76-84.
20. Evers BM, Townsend CMJ, Thompson JC. Organ physiology of aging. Surg Clin North Am 1994; 60: 1121-39.
21. Mangioni C, Bolis G, Pecorelli S, et al. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 1989; 81: 1464-71.
22. Becouarn Y, Bui BN, Burnet R, et al. Cancer chemotherapy in the elderly: A series of 51 patients aged >70 years. Cancer Chemother Pharmacol 1992; 29: 159-63.
23. Thyss A, Saudes L, Otto J, et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994; 12: 2121-5.
24. Dangaard G, Abilgaard U. Cisplatin nephrotoxicity. Cancer Chemother Pharmacol 1988; 25: 1-9.
25. Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical spectrum to date. Cancer Treat Rev 1985; 12: 125-36.
26. Taylor AE, Wiltshaw E, Gore ME, et al. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 1994; 12: 2066-70.
27. Conte PF, Bruzzone M, Carmine F, et al. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide. A randomized trial in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 1991; 9: 658-63.
28. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage-prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-56.
29. Egorin MJ, Van Echo DA, Tipping SJ, et al. Pharmacokinetics and dosage reduction of cis-diammino (1,1-cyclobutanildicarboxylato) platinum in patients with impaired renal function. Cancer Res 1984; 44: 5432-8.
30. Cornelison TL, Reed E. Dose-intensity analysis of high-dose carboplatin in refractory ovarian carcinoma relative to age. Cancer 1993; 71 (Suppl.): 650-5.
31. Bicher A, Sarosy G, Kohn E, et al. Age does not influence Taxol dose-intensity in recurrent carcinoma of the ovary. Cancer 1993; 71 (Suppl.): 594-600.
32. Markman M, Lewis JL, Saigo P, et al. Epithelial ovarian cancer in the elderly. Cancer 1993; 71 (Suppl.): 634-7.
33. Calvert AH, Boddy A, Bailey NP, et al. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 1995; 22 (Suppl. 12): 91-8.
34. Desh CE, Smith TJ. Defining treatment aims and end-points in older patients with cancer. Drugs Aging 1995; 6: 351-7.
35. McKenna RJ. Clinical aspects of cancer in the elderly, treatment decisions, treatment choices and follow-up. Cancer 1994; 74: 2107-17.
36. Kinzel T, Feleppa V. Minimizing the side effects of cancer chemotherapy in senior patients. Drugs Aging 1992; 2: 137-45.
37. Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer 1994; 74: 2208-14.